BIOactive

Just an observer with an occasional position to play. Nothing I ever say should be taken as advice. Do your own DD and may the market be with you!

[BIOactive @TradingBio]

@WallStreetApes You can’t paint the entire industry with one color - I am sure some of this may exist (or more realistically DID exist) but the true reality is that those days are long gone. The last time any of this was rampant was in the late 90’s - progressive compliance regs block it all now

[BIOactive @TradingBio]

@BIOTECHSCANNER I remember hearing that & agree - I’m a long time veteran in the space and unfortunately have see this strategy go sideways in the past where a company has to scramble to build a commercial presence. Launch suffers and value evaporates. I believe in this long term - just cautious

[BIOactive @TradingBio]

I’m looking at $PFE data for the drug they just announced - it’s going to be a tough road and it offers no advantage over $VKTX. If anything, the safety is suspect…the drug was shelved a few years back due to toxicity so it’s odd that they are now advancing it. Feels desperate.

[BIOactive @TradingBio]

@Biotech2k1 Count me in

[BIOactive @TradingBio]

@pawcio2009 @PersimmonTI A broken clock is correct twice a day…you keep saying this and one day you will be right, Pawcio!

[BIOactive @TradingBio]

@StuckInStock Why $CLRB isn’t doubled on this I can’t figure out. We will see how the day trades…

[BIOactive @TradingBio]

@crypto_biotech Not really sure how to interpret their actions. The bear thesis here is that the data isn’t great and they are trying to stabilize the company before announcing results - reassuring investors they have a cash runway and protecting the share price from dropping to pennies $EFTR

[BIOactive @TradingBio]

$EFTR RS is way overdone.

[BIOactive @TradingBio]

@bio_2023 And my investment is my donation (sometimes)!

[BIOactive @TradingBio]

@bio_2023 That is the unfortunate reality. Innovation does not always match with the ability to generate alpha.

For what it’s worth I’m always up for debate so appreciate the back-and-forth and not going to personal attacks - cheers!

[BIOactive @TradingBio]

@bio_2023 In the end, I don’t expect the market to behave ethically, but when companies like these are targeted for no reason other than pettiness, they destroy innovation before it has the chance to see the light of day. Especially in painful in the rare dx space where pts are waiting.

[BIOactive @TradingBio]

@bio_2023 And that further handicaps innovation. As to your earlier point, I did jump into $XFOR and I just started a position in $EFTR. Still not sold on $LEAP I’m looking back at some rather interesting management decisions but time will tell.

[BIOactive @TradingBio]

@bio_2023 So yes - company value is subjective, but when the whales you speak of become market makers their focused attention (esp in a negative fashion) has long lasting impact on the company in their ability to raise further capital and properly develop their medicines.

[BIOactive @TradingBio]

@bio_2023 What happens in these cases is that the company gets squeezed and the longer the pressure is applied, the greater the potential for their innovation to die on the vine - potetnially even before the concept is proven.

[BIOactive @TradingBio]

@bio_2023 For the same reason I avoid clear pumping, which creates artificial value I look at the value destruction created by short HF and institutions that specifically seem to target some names for no reason other than they happen to be on a Twit list I

[BIOactive @TradingBio]

@bio_2023 Believe it not I don’t disagree with you. It’s the sinple law of economics that drives pricing: supply and demand. Where I find fault with this particular application of economic principles is that the pressures driving the price action aren’t always aligned with the patient need

[BIOactive @TradingBio]

@bio_2023 But a $26m MC is rediculous - should easily be 2-3x where it is today. $LPTX was pummeled earlier this year but they were heavily diluted and need the RS. The lower valuation just accelerated that need…tough to really gauge FMV on this one as I’m not that close to the data.

[BIOactive @TradingBio]

@bio_2023 But feet to the fire, I would say $XFOR (currently) should be holding over $1 - $1.50 with the PRV…company MC is equivalent to the value of the PRV alone. $EFTR is a longer play - I think they have a good deal with PFE for their early stage programs but time will tell.

[BIOactive @TradingBio]

@bio_2023 I picked the major retail darlings - not necessarily as commentary on specific valuations but, rather, a call out to those short funds that solely target microcap bios that happen to be top “Twitter picks”…sorry “X picks”